Average Insider

Where insiders trade, we follow

$FRMM
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Healthcare
Sector
Biotechnology
Industry
Lloyd Blair Jordan
CEO
4
Employees
$5.90
Current Price
$1.08B
Market Cap
52W Low$1.76
Current$5.902.4% above low, 97.6% below high
52W High$174.60

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00--All Sells
Sells12$30,476.894,802
2 weeksBuys00--All Sells
Sells12$30,476.894,802
1 monthBuys00--All Sells
Sells12$30,476.894,802
2 monthsBuys00--All Sells
Sells12$30,476.894,802
3 monthsBuys00--All Sells
Sells12$30,476.894,802
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Jul 7, 2026
Lomashuk Konstantin
10% Owner
Sale3,702$6.41$23,733.89View Details
Jul 8, 2026
Lomashuk Konstantin
10% Owner
Sale1,100$6.13$6,743.00View Details

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Version: v26.5.2